Comparative aspects of treatment of endometrial hyperplasia in women of reproductive age with overweight

The aim. Minimization of the frequency recurrence endometrial hyperplasia (EH) in women reproductive age with overweight (OW) depending on tactics treatment.
 Materials and methods. 90 OW were selected. They, turn, divided into three groups: group 1 – 30 who took a gonadotropin-releasing hormone agonist (GnRH agonist), namely at dose 3.75 mg intramuscularly once every 28 days; 2 used progestin (norethisterone) 10 per day from 16 to 25 cycle, 3 combined oral contraception (COC) (30 mcg ethinyl estradiol 150 desogestrel) cyclic mode 21/7.
 Evaluation effectiveness therapy included clinical picture disease 6 months after start treatment, assessment variability average values thickness uterine size ultrasound (US) pelvis treatment. Also analyzed based results morphological examination endometrium biopsy mucosa, performed In addition, general analysis EH was 6–24 Results. showed that which prescribed GnRH agonist, there significantly higher particular absence bleeding menstrual disorders (MD). At same time, other norethisterone group, 53.3 % (16) had intermenstrual bleeding. patients received COC, observed 30.0 (i.e. 9) (p <0.05).
 Immediately 1, according ultrasound, 3.59±0.47 mm, less than groups 6.81±0.59 mm (p<0.001) 7.58±0.69 (p<0.001).
 3, 6, 12, 24 end registered lower thickness, compared receiving estrogen-progestogen drugs.
 Conclusions. comparative evaluation treatment hyperplastic processes women, it found rate occurs 6.7 2) therapy, 33.3 10) (p<0.001), 50 15) treated COC (p<0.001).